NEW YORK ( TheStreet) -- CHANGE IN RATINGSAlexion Pharmaceuticals ( ALXN) initiated at Credit Suisse with an Outperform rating and $55 price target. 2010 and 2011 EPS estimates set at $1.24 and $2.56, respectively. Boeing ( BA) upgraded at Oppenheimer. BA was upgraded from Underperform to Outperform. Company will accelerate production of 777 and 747 planes. BioMarin Pharmaceutical ( BMRN) initiated at Credit Suisse with an Outperform rating and $27 price target. 2010 and 2011 EPS estimates set at 11 cents and 42 cents, respectively. Capitol Federal Financial ( CFFN) initiated at Barclays with an Overweight rating and $43 price target. Overcapitalized and best in class credit quality. 2010 and 2011 EPS estimates set at 98 cents and 94 cents, respectively. Cytokinetics ( CYTK) initiated at Credit Suisse with an Outperform rating and $9 price target. 2010 and 2011 EPS estimates set at -$0.77 and -$0.73, respectively. Expeditors Int'l. ( EXPD) rated new Underweight at Morgan Stanley. EXPD was initiated with an Underweight rating. It's still premature to rotate into later-cycle transportation names. Genuine Parts ( GPC) upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction List. Estimates raised, as the company can recapture market share in the automotive sector. $48 price target. IAC/InterActive ( IACI) downgraded at UBS from Buy to Neutral. $24 price target. Valuation call, as the stock is up 34% since last July. Jack In The Box ( JBX) downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Price target raised to $24 from $22. 2010 EPS estimates maintained at $1.92. Lockheed Martin ( LMT) downgraded at Oppenheimer from Outperform to Perform. Valuation call, based on a $90 price target. OfficeMax ( OMX) downgraded at Goldman to Neutral. Valuation call, based on an $18.50 price target. Ryland ( RYL) downgraded at Wells from Outperform to Market Perform. Valuation call. Verisign ( VRSN) downgraded at Oppenheimer. VRSN was downgraded from Outperform to Perform. Valuation call, as there's little room for margin expansion. Waddell & Reed ( WDR) upgraded at FBR to Outperform. $40 price target. Company should be able to deliver above-average asset inflow and earnings growth.